Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Hewlett Packard Enterprise Co (HPE) vs Nuwellis Inc (NUWE) Price & Performance

Hewlett Packard Enterprise CoTrade
Nuwellis IncTrade

Price performance (Past 24H)

Key statistics

Hewlett Packard Enterprise Co vs Nuwellis Inc — how do they compare? Hewlett Packard Enterprise Co trades at $46.59 (market cap $59.01B), while Nuwellis Inc trades at $2.9 (market cap $1.09M). The key difference: Hewlett Packard Enterprise Co is far larger — about 54137.6× Nuwellis Inc's market cap, and Hewlett Packard Enterprise Co pays a 1.28% dividend while Nuwellis Inc pays none. Which is the better fit depends on your goals.

HPENUWE
Market Cap
$59.01B$1.09M
Sector
TechnologyTechnology
52-Week High
$56.14$527.46
52-Week Low
$19.81$2.80
Enterprise Value
$74.96B-$722.58K
Dividend Yield
1.28%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Hewlett Packard Enterprise Co

HPE trades at $44.95, down 1.9% today, with a bearish technical signal despite recent earnings beats. The stock shows strong AI infrastructure momentum with a record $6.3 billion backlog, though 2025 net income declined sharply to $57 million. Valuation metrics include a P/E of 42.8 and P/S of 1.6, while analyst consensus favors a Buy rating with a $69.69 price target representing 55% upside potential.

HPE's transformation into an AI infrastructure leader presents significant growth opportunity, supported by strong enterprise demand and improving cash flow projections. Key risks include competitive pressure in AI hardware, execution challenges with Juniper integration, and volatile cash flow patterns. The current valuation appears reasonable given AI growth prospects despite near-term profitability concerns.

Nuwellis Inc

NUWE trades at $3.00, up 5.26% today, following a 35:1 reverse stock split effective June 26, 2026. The company shows a low P/E of 0.06 and P/S of 0.01, but fundamentals are weak with a -217.22% net income margin and negative ROE. Recent news highlights patent awards and pediatric market expansion, yet cash flow remains negative. Analyst coverage is limited with a split buy/hold consensus.

Outlook is speculative; growth depends on successful commercialization of Aquadex therapy and cost management. Key risks include persistent losses, high cash burn, and competitive pressures. Investors should weigh low valuation against execution risks in the medical technology sector.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Hewlett Packard Enterprise Co

Hewlett Packard Enterprise is an information technology vendor that provides hardware and software to enterprises. Its primary product lines are compute servers, storage arrays, and networking equipment.

Read more on HPE

About Nuwellis Inc

Nuwellis, Inc. is a medical device company focused on developing and commercializing fluid management solutions. The company's primary product is an ultrafiltration system used in hospitals to remove excess fluid from patients with fluid overload, often associated with conditions such as heart and kidney failure. Nuwellis aims to improve patient outcomes and reduce healthcare costs through its specialized, innovative therapies.

Read more on NUWE